Загрузка...
Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This review provides a summary of the cumulative dataset fro...
Сохранить в:
| Опубликовано в: : | Ther Adv Neurol Disord |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4784254/ https://ncbi.nlm.nih.gov/pubmed/27006700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616628766 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|